<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02875080</url>
  </required_header>
  <id_info>
    <org_study_id>331-102-00019</org_study_id>
    <secondary_id>JapicCTI-163351</secondary_id>
    <nct_id>NCT02875080</nct_id>
  </id_info>
  <brief_title>Evaluation Study of the Bioavailability of Brexpiprazole Orally Disintegrating Tablets in Healthy Male Subjects</brief_title>
  <official_title>A Single-center, Open-label, Randomized, Three-way, Crossover Trial to Evaluate the Bioavailability of Brexpiprazole (OPC-34712) Orally Disintegrating Tablets Relative to Brexpiprazole (OPC-34712) Conventional Tablets in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ratios of the geometric means of the ODT formulation to those of the reference
      formulation (conventional tablet) for the bioavailability variables (Cmax, AUCt, and AUC∞ of
      brexpiprazole (OPC-34712)).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 27, 2016</start_date>
  <completion_date type="Actual">November 27, 2016</completion_date>
  <primary_completion_date type="Actual">November 27, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of OPC-34712</measure>
    <time_frame>Pre pose, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72, 96, 120，144, 168, 216, 264, and 312 hours postdose</time_frame>
    <description>To evaluate Cmax of OPC-34712 4-mg ODT formulation relative to 4-mg conventional tablet formulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of OPC-34712</measure>
    <time_frame>Pre pose, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72, 96, 120，144, 168, 216, 264, and 312 hours postdose</time_frame>
    <description>To evaluate AUC of OPC-34712 4-mg ODT formulation relative to 4-mg conventional tablet formulation</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy Adult Male</condition>
  <arm_group>
    <arm_group_label>OPC-34712 disintegrating tablet with water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC-34712 (4 mg) orally disintegrating tablet is administered with water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPC-34712 disintegrating tablet without water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC-34712 (4 mg) orally disintegrating tablet is administered without water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPC-34712 conventional tablet with water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC-34712 (4 mg) conventional tablet is administered with water.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC-34712</intervention_name>
    <arm_group_label>OPC-34712 disintegrating tablet with water</arm_group_label>
    <arm_group_label>OPC-34712 disintegrating tablet without water</arm_group_label>
    <arm_group_label>OPC-34712 conventional tablet with water</arm_group_label>
    <other_name>Brexpiprazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capable of providing written informed consent prior to initiation of any trial-related
             procedures, and able, in the opinion of the investigator, to comply with all
             requirements of the trial

        Exclusion Criteria:

          -  Clinically significant abnormality at the time of screening (eg, significant deviation
             from reference ranges) or in medical history that, in the opinion of investigator or
             sponsor may place the subject at risk or interfere with outcome variables, including
             drug absorption, distribution, metabolism, and excretion

          -  History of serious mental disorder

          -  History of drug or alcohol abuse within 2 years prior to screening

          -  History of any significant drug allergy

          -  Use of an investigational drug within 120 days prior to the first dosing of trial drug

          -  Use of tobacco products or daily exposure to secondhand smoke within 2 months prior to
             screening

          -  Consumption of grapefruit, grapefruit products, Seville oranges, Seville orange
             products, starfruit, or starfruit products within 72 hours prior to dosing

          -  Use of prescription, over-the-counter, or herbal medication, vitamin supplements, or
             St. John's Wort within 14 days prior to the first dosing of trial drug, or of
             antibiotics within 30 days prior to the first dosing of trial drug

          -  History of major surgery of the digestive tract (excluding appendectomy)

          -  Any subject who, in the opinion of the investigator, should not participate in the
             trial
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroaki Ono, Mr</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kyusyu Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2016</study_first_submitted>
  <study_first_submitted_qc>August 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2016</study_first_posted>
  <last_update_submitted>December 22, 2017</last_update_submitted>
  <last_update_submitted_qc>December 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brexpiprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

